Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ischemic Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 265 articles:
HTML format
Text format



Single Articles


    July 2018
  1. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    PubMed     Text format     Abstract available


  2. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Text format     Abstract available


  3. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    PubMed     Text format     Abstract available


    June 2018
  4. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available


  5. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    PubMed     Text format    


  6. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Text format     Abstract available


  7. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    PubMed     Text format     Abstract available


  8. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Text format     Abstract available


  9. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Text format     Abstract available


  10. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    PubMed     Text format     Abstract available


  11. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    PubMed     Text format     Abstract available


  12. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Text format     Abstract available


  13. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    PubMed     Text format     Abstract available


  14. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Text format     Abstract available


  15. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available


    May 2018
  16. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    PubMed     Text format     Abstract available


  17. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Text format     Abstract available


  18. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    PubMed     Text format    


  19. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    PubMed     Text format     Abstract available


  20. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Text format     Abstract available


  21. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Text format     Abstract available


  22. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Text format     Abstract available


  23. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    PubMed     Text format     Abstract available


  24. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    PubMed     Text format     Abstract available


  25. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    PubMed     Text format     Abstract available


  26. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    PubMed     Text format    


  27. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    PubMed     Text format     Abstract available


  28. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    PubMed     Text format     Abstract available


  29. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Text format     Abstract available


  30. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
    Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
    Am Heart J. 2018;199:122-129.
    PubMed     Text format     Abstract available


    April 2018
  31. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
    Validation of the Seattle angina questionnaire in women with ischemic heart disease.
    Am Heart J. 2018;201:117-123.
    PubMed     Text format     Abstract available


  32. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
    Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
    Am Heart J. 2018;202:61-67.
    PubMed     Text format     Abstract available


  33. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
    Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
    Am Heart J. 2018;202:33-38.
    PubMed     Text format     Abstract available


  34. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Text format     Abstract available


  35. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Am Heart J. 2018;202:27-32.
    PubMed     Text format     Abstract available


  36. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Text format     Abstract available


  37. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
    Am Heart J. 2018;201:86-94.
    PubMed     Text format     Abstract available


  38. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    PubMed     Text format     Abstract available


  39. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
    Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
    Am Heart J. 2018;198:91-96.
    PubMed     Text format     Abstract available


  40. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    PubMed     Text format     Abstract available


  41. CACOUB P, Nahon P, Layese R, Blaise L, et al
    Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
    Am Heart J. 2018;198:4-17.
    PubMed     Text format     Abstract available


  42. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    PubMed     Text format     Abstract available


  43. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
    Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
    Am Heart J. 2018;198:180-188.
    PubMed     Text format     Abstract available


  44. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
    Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
    Am Heart J. 2018;198:18-24.
    PubMed     Text format     Abstract available


  45. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
    Government continues to have an important role in promoting cardiovascular health.
    Am Heart J. 2018;198:160-165.
    PubMed     Text format    


  46. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    PubMed     Text format     Abstract available


    March 2018
  47. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
    Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Am Heart J. 2018;202:39-48.
    PubMed     Text format     Abstract available


  48. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
    Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
    Am Heart J. 2018;202:89-96.
    PubMed     Text format     Abstract available


  49. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    PubMed     Text format     Abstract available


  50. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    PubMed     Text format     Abstract available


  51. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    PubMed     Text format     Abstract available


  52. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    PubMed     Text format     Abstract available


  53. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    PubMed     Text format     Abstract available


  54. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    PubMed     Text format     Abstract available


  55. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    PubMed     Text format     Abstract available


  56. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    PubMed     Text format     Abstract available


  57. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Text format     Abstract available


  58. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Text format     Abstract available


  59. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    PubMed     Text format     Abstract available


    February 2018
  60. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    PubMed     Text format     Abstract available


  61. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    PubMed     Text format     Abstract available


  62. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    PubMed     Text format     Abstract available


  63. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    PubMed     Text format     Abstract available


  64. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    PubMed     Text format     Abstract available


  65. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
    Biomarkers in stable coronary artery disease.
    Am Heart J. 2018;196:82-96.
    PubMed     Text format     Abstract available


  66. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    PubMed     Text format     Abstract available


  67. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
    Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
    Am Heart J. 2018;196:170-177.
    PubMed     Text format     Abstract available


  68. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
    How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
    Am Heart J. 2018;196:163-169.
    PubMed     Text format     Abstract available


  69. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Text format     Abstract available


    January 2018
  70. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    PubMed     Text format     Abstract available


  71. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
    Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Am Heart J. 2018;195:78-85.
    PubMed     Text format     Abstract available


  72. ISSA OM, Roberts R, Mark DB, Boineau R, et al
    Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Am Heart J. 2018;195:70-77.
    PubMed     Text format     Abstract available


  73. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
    Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
    Am Heart J. 2018;195:60-69.
    PubMed     Text format     Abstract available


  74. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    PubMed     Text format     Abstract available


  75. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
    Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Am Heart J. 2018;195:151-152.
    PubMed     Text format    


  76. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
    Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
    Am Heart J. 2018;195:1-13.
    PubMed     Text format     Abstract available


    December 2017
  77. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    PubMed     Text format     Abstract available


  78. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    PubMed     Text format     Abstract available


  79. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    PubMed     Text format     Abstract available


  80. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
    Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
    Am Heart J. 2017;194:16-24.
    PubMed     Text format     Abstract available


  81. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
    Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
    Am Heart J. 2017;194:116-124.
    PubMed     Text format     Abstract available


  82. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    PubMed     Text format     Abstract available


    November 2017
  83. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    PubMed     Text format     Abstract available


  84. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Text format     Abstract available


  85. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    PubMed     Text format     Abstract available


  86. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Text format     Abstract available


  87. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    PubMed     Text format     Abstract available


  88. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    PubMed     Text format     Abstract available


  89. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Text format     Abstract available


    October 2017
  90. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    PubMed     Text format     Abstract available


  91. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    PubMed     Text format     Abstract available


  92. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


  93. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    PubMed     Text format     Abstract available


    September 2017
  94. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    PubMed     Text format     Abstract available


  95. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Text format     Abstract available


  96. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    PubMed     Text format    


  97. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    PubMed     Text format     Abstract available


  98. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    PubMed     Text format     Abstract available


  99. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Text format     Abstract available


    August 2017
  100. BAGAI A, Alexander KP, Berger JS, Senior R, et al
    Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis.
    Am Heart J. 2017;190:135-139.
    PubMed     Text format     Abstract available


  101. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Text format     Abstract available


  102. IVERS N, Schwalm JD, Witteman HO, Presseau J, et al
    Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol.
    Am Heart J. 2017;190:64-75.
    PubMed     Text format     Abstract available


  103. PALMERINI T, Serruys P, Kappetein AP, Genereux P, et al
    Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.
    Am Heart J. 2017;190:54-63.
    PubMed     Text format     Abstract available


  104. JIANG R, Babyak MA, Brummett BH, Hauser ER, et al
    Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort.
    Am Heart J. 2017;190:40-45.
    PubMed     Text format     Abstract available


  105. PAPENDICK C, Blyth A, Seshadri A, Edmonds MJR, et al
    A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study.
    Am Heart J. 2017;190:25-33.
    PubMed     Text format     Abstract available


  106. SARA JDS, Prasad M, Zhang M, Lennon RJ, et al
    High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease.
    Am Heart J. 2017;190:1-11.
    PubMed     Text format     Abstract available


  107. HAMM W, Rizas KD, Stulpnagel LV, Vdovin N, et al
    Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: Design and rationale of the SMART-MI trial.
    Am Heart J. 2017;190:34-39.
    PubMed     Text format     Abstract available


    July 2017
  108. FROBERT O, Gotberg M, Angeras O, Jonasson L, et al
    Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.
    Am Heart J. 2017;189:94-102.
    PubMed     Text format     Abstract available


  109. NAGARAJAN V, Fonarow GC, Ju C, Pencina M, et al
    Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;189:85-93.
    PubMed     Text format     Abstract available


  110. LEWIS EF, Wang R, Punjabi N, Gottlieb DJ, et al
    Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis.
    Am Heart J. 2017;189:59-67.
    PubMed     Text format     Abstract available


  111. VEMULAPALLI S, Lippmann SJ, Krucoff M, Hernandez AF, et al
    Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients.
    Am Heart J. 2017;189:146-157.
    PubMed     Text format     Abstract available


  112. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    PubMed     Text format     Abstract available


    June 2017
  113. SELKER HP, Udelson JE, Ruthazer R, D'Agostino RB, et al
    Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials.
    Am Heart J. 2017;188:18-25.
    PubMed     Text format     Abstract available


  114. KEDHI E, Fabris E, van der Ent M, Kennedy MW, et al
    A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Am Heart J. 2017;188:11-17.
    PubMed     Text format     Abstract available


  115. BABER U, Sartori S, Aquino M, Kini A, et al
    Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
    Am Heart J. 2017;188:73-81.
    PubMed     Text format     Abstract available


  116. VEDANTHAN R, Kamano JH, Lee H, Andama B, et al
    Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study.
    Am Heart J. 2017;188:175-185.
    PubMed     Text format     Abstract available


  117. DALBY AJ, Gottlieb S, Cyr DD, Magnus Ohman E, et al
    Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
    Am Heart J. 2017;188:156-166.
    PubMed     Text format     Abstract available


  118. ABNOUSI F, Sundaram V, Yong CM, Prats J, et al
    Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Am Heart J. 2017;188:147-155.
    PubMed     Text format     Abstract available


  119. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    PubMed     Text format     Abstract available


  120. MELINA G, Angeloni E, Refice S, Monti F, et al
    Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.
    Am Heart J. 2017;188:118-126.
    PubMed     Text format     Abstract available


  121. COUTE RA, Ehrenfeld JM, Gupta DK, Terekhov MA, et al
    Electronically self-assessed functional capacity and exercise testing: A comparison of the Duke Activity Status Index and Patient-Reported Outcomes Measurement Information System tools.
    Am Heart J. 2017;188:82-86.
    PubMed     Text format     Abstract available


  122. WIDMER RJ, Allison TG, Lennon R, Lopez-Jimenez F, et al
    Digital health intervention during cardiac rehabilitation: A randomized controlled trial.
    Am Heart J. 2017;188:65-72.
    PubMed     Text format     Abstract available


  123. KIM YG, Suh JW, Sibbing D, Kastrati A, et al
    A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis.
    Am Heart J. 2017;188:53-64.
    PubMed     Text format     Abstract available


  124. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    PubMed     Text format     Abstract available


    May 2017
  125. KAWADA T
    beta-Blocker after acute myocardial infarction.
    Am Heart J. 2017;187:e1.
    PubMed     Text format    


  126. BAGAI A, Peterson ED, McCoy LA, Effron MB, et al
    Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of
    Am Heart J. 2017;187:19-28.
    PubMed     Text format     Abstract available


  127. KONG DF, Saito S, Nakamura S, Mehran R, et al
    Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic cor
    Am Heart J. 2017;187:112-121.
    PubMed     Text format     Abstract available


  128. DEEDWANIA P, Acharya T, Kotak K, Fonarow GC, et al
    Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;187:78-87.
    PubMed     Text format     Abstract available


  129. PAGIDIPATI NJ, Hess CN, Clare RM, Akerblom A, et al
    An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
    Am Heart J. 2017;187:53-61.
    PubMed     Text format     Abstract available


  130. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    PubMed     Text format     Abstract available


  131. LAVI S, Dzavik V
    Recurrent MI and stroke post-acute coronary syndrome: Which is the lesser evil?
    Am Heart J. 2017;187:191-193.
    PubMed     Text format    


  132. LEMMERT ME, Oldroyd K, Barragan P, Lesiak M, et al
    Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicent
    Am Heart J. 2017;187:104-111.
    PubMed     Text format     Abstract available


  133. SCIAHBASI A, Rigattieri S, Sarandrea A, Cera M, et al
    Determinants of operator radiation exposure during percutaneous coronary procedures.
    Am Heart J. 2017;187:10-18.
    PubMed     Text format     Abstract available


  134. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    PubMed     Text format     Abstract available


  135. FENDER EA, Liang JJ, Sio TT, Stulak JM, et al
    Percutaneous revascularization in patients treated with thoracic radiation for cancer.
    Am Heart J. 2017;187:98-103.
    PubMed     Text format     Abstract available


  136. FINESCHI M, Verna E, Mezzapelle G, Bartolini D, et al
    Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): Rationale and design of a prospective multicenter clinical trial.
    Am Heart J. 2017;187:37-44.
    PubMed     Text format     Abstract available


  137. LANDRAY MJ, Reveal Collaborative Group
    Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitmen
    Am Heart J. 2017;187:182-190.
    PubMed     Text format     Abstract available


    April 2017
  138. SMITS PC, Assaf A, Richardt G, Omerovic E, et al
    Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients
    Am Heart J. 2017;186:21-28.
    PubMed     Text format     Abstract available


  139. QINTAR M, Spertus JA, Tang Y, Buchanan DM, et al
    Noncardiac chest pain after acute myocardial infarction: Frequency and association with health status outcomes.
    Am Heart J. 2017;186:1-11.
    PubMed     Text format     Abstract available


  140. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    PubMed     Text format     Abstract available


  141. SHARMA A, de Souza Brito F, Sun JL, Thomas L, et al
    Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcom
    Am Heart J. 2017;186:73-82.
    PubMed     Text format     Abstract available


  142. ENGBERS EM, Timmer JR, Mouden M, Knollema S, et al
    Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients.
    Am Heart J. 2017;186:56-62.
    PubMed     Text format     Abstract available


  143. LEE SE, Lin FY, Lu Y, Chang HJ, et al
    Rationale and design of the Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life (CONSERVE) trial.
    Am Heart J. 2017;186:48-55.
    PubMed     Text format     Abstract available


  144. HANNAN EL, Zhong Y, Jacobs AK, Ling FSK, et al
    Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.
    Am Heart J. 2017;186:118-126.
    PubMed     Text format     Abstract available


    March 2017
  145. LOU B, Gao H, Zhou C
    Remote ischemic conditioning in ST-segment elevation myocardial infarction: Effect of coronary collateral circulation.
    Am Heart J. 2017;185:e1.
    PubMed     Text format    


  146. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    PubMed     Text format     Abstract available


  147. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    PubMed     Text format     Abstract available


  148. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


  149. KHETAN A, Purushothaman R, Zullo M, Gupta R, et al
    Rationale and design of a cluster-randomized controlled trial to evaluate the effects of a community health worker-based program for cardiovascular risk factor control in India.
    Am Heart J. 2017;185:161-172.
    PubMed     Text format     Abstract available


  150. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    PubMed     Text format     Abstract available


  151. YUSUF S, Joseph P
    The epidemic of cardiovascular disease in South Asians: Time for action.
    Am Heart J. 2017;185:150-153.
    PubMed     Text format    


  152. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  153. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Text format     Abstract available


    February 2017
  154. VARENHORST C, Johnston N
    RE: Letter to the editor, Dr Cheng et al. "Smartphone apps and secondary prevention after myocardial infarction-How can long-term usage be improved?"
    Am Heart J. 2017;184:e2.
    PubMed     Text format    


  155. CHENG K, Oswal A
    Smartphone apps and secondary prevention after myocardial infarction - How can long-term usage be improved?
    Am Heart J. 2017;184:e1.
    PubMed     Text format    


  156. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


  157. WELSH RC, Roe MT, Steg PG, James S, et al
    Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100].
    Am Heart J. 2017;184:156.
    PubMed     Text format    


  158. NEWMAN JD, Rockman CB, Kosiborod M, Guo Y, et al
    Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.
    Am Heart J. 2017;184:114-120.
    PubMed     Text format     Abstract available


  159. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


  160. VOORA D, Coles A, Lee KL, Hoffmann U, et al
    An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2017;184:133-140.
    PubMed     Text format     Abstract available


  161. COFFENG JK, van der Ploeg HP, Castellano JM, Fernandez-Alvira JM, et al
    A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial.
    Am Heart J. 2017;184:121-132.
    PubMed     Text format     Abstract available


  162. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  163. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    PubMed     Text format     Abstract available


  164. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Text format     Abstract available


  165. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    PubMed     Text format     Abstract available


  166. SENTHONG V, Wu Y, Hazen SL, Tang WH, et al
    Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index.
    Am Heart J. 2017;184:17-25.
    PubMed     Text format     Abstract available


    January 2017
  167. SHERWOOD A, Smith PJ, Hinderliter AL, Georgiades A, et al
    Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial.
    Am Heart J. 2017;183:85-90.
    PubMed     Text format     Abstract available


  168. LU Y, Zhou S, Dreyer RP, Caulfield M, et al
    Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.
    Am Heart J. 2017;183:74-84.
    PubMed     Text format     Abstract available


  169. ZETTLER ME, Peterson ED, McCoy LA, Effron MB, et al
    Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events a
    Am Heart J. 2017;183:62-68.
    PubMed     Text format     Abstract available


  170. BOCCARA F, Miantezila Basilua J, Mary-Krause M, Lang S, et al
    Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.
    Am Heart J. 2017;183:91-101.
    PubMed     Text format     Abstract available


  171. VENKATESH BA, Nauffal V, Noda C, Fujii T, et al
    Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cel
    Am Heart J. 2017;183:24-34.
    PubMed     Text format     Abstract available


  172. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    PubMed     Text format     Abstract available


    December 2016
  173. AU YEUNG SL, Lin SL, Lam HS, Schooling CM, et al
    Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study.
    Am Heart J. 2016;182:54-61.
    PubMed     Text format     Abstract available


  174. RODRIGUEZ F, Lin S, Maron DJ, Knowles JW, et al
    Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
    Am Heart J. 2016;182:97-102.
    PubMed     Text format     Abstract available


  175. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    PubMed     Text format     Abstract available


  176. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    PubMed     Text format     Abstract available


  177. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    PubMed     Text format     Abstract available


  178. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    PubMed     Text format     Abstract available


  179. LEE SE, Chang HJ, Rizvi A, Hadamitzky M, et al
    Rationale and design of the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry: A comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter seri
    Am Heart J. 2016;182:72-79.
    PubMed     Text format     Abstract available


    November 2016
  180. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  181. WELSH RC, Roe MT, Steg PG, James S, et al
    A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
    Am Heart J. 2016;181:92-100.
    PubMed     Text format     Abstract available


  182. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    PubMed     Text format     Abstract available


  183. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    PubMed     Text format     Abstract available


  184. MONDESIR FL, Brown TM, Muntner P, Durant RW, et al
    Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).
    Am Heart J. 2016;181:43-51.
    PubMed     Text format     Abstract available


  185. RERUP SA, Bang LE, Mogensen UM, Engstrom T, et al
    The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
    Am Heart J. 2016;181:35-42.
    PubMed     Text format     Abstract available


  186. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    PubMed     Text format     Abstract available


  187. WILDI K, Nelles B, Twerenbold R, Rubini Gimenez M, et al
    Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction.
    Am Heart J. 2016;181:16-25.
    PubMed     Text format     Abstract available


  188. VIRANI SS, Akeroyd JM, Ramsey DJ, Chan WJ, et al
    Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act.
    Am Heart J. 2016;181:74-82.
    PubMed     Text format     Abstract available


  189. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    PubMed     Text format     Abstract available


  190. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


  191. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


    October 2016
  192. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    PubMed     Text format     Abstract available


  193. AGARWAL SK, Kasula S, Almomani A, Hacioglu Y, et al
    Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization.
    Am Heart J. 2016;184:10-16.
    PubMed     Text format     Abstract available


  194. SHAH R, Yow E, Jones WS, Kohl LP 3rd, et al
    Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2016;184:1-9.
    PubMed     Text format     Abstract available


  195. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    PubMed     Text format     Abstract available


  196. MCCARTHY CP, McEvoy JW
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection-reply.
    Am Heart J. 2016;180:e7-8.
    PubMed     Text format    


  197. RUAN X, Chiravuri S, Kaye AD
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection.
    Am Heart J. 2016;180:e5-6.
    PubMed     Text format    


  198. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    PubMed     Text format     Abstract available


  199. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    PubMed     Text format     Abstract available


  200. NGUYEN TL, Phan J, Hogan J, Hee L, et al
    Adverse diastolic remodeling after reperfused ST-elevation myocardial infarction: An important prognostic indicator.
    Am Heart J. 2016;180:117-27.
    PubMed     Text format     Abstract available


  201. SUMMERS MR, Menon V
    Insights from cardiac imaging after ST-elevation myocardial infarction: Will increased recognition of patients at risk translate into improved long-term outcomes?
    Am Heart J. 2016;180:113-6.
    PubMed     Text format    


  202. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    PubMed     Text format     Abstract available


  203. GIBSON CM, Korjian S, Tricoci P, Daaboul Y, et al
    Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute
    Am Heart J. 2016;180:22-8.
    PubMed     Text format     Abstract available


    September 2016
  204. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    PubMed     Text format     Abstract available


  205. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Text format     Abstract available


  206. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    PubMed     Text format    


  207. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  208. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    PubMed     Text format     Abstract available


  209. BHATNAGAR A, Bolli R, Johnstone BH, Traverse JH, et al
    Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
    Am Heart J. 2016;179:142-50.
    PubMed     Text format     Abstract available


  210. HAO Y, Liu J, Liu J, Smith SC Jr, et al
    Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
    Am Heart J. 2016;179:107-15.
    PubMed     Text format     Abstract available


  211. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


    August 2016
  212. ABATE E, Hoogslag GE, Al Amri I, Debonnaire P, et al
    Time course, predictors, and prognostic implications of significant mitral regurgitation after ST-segment elevation myocardial infarction.
    Am Heart J. 2016;178:115-25.
    PubMed     Text format     Abstract available


  213. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    PubMed     Text format     Abstract available


  214. JOHNSTON N, Bodegard J, Jerstrom S, Akesson J, et al
    Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
    Am Heart J. 2016;178:85-94.
    PubMed     Text format     Abstract available


  215. SUTTON NR, Li S, Thomas L, Wang TY, et al
    The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked dat
    Am Heart J. 2016;178:65-73.
    PubMed     Text format     Abstract available


  216. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    PubMed     Text format     Abstract available


  217. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    PubMed     Text format    


  218. ARMAGANIJAN LV, Alexander KP, Huang Z, Tricoci P, et al
    Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2016;178:176-84.
    PubMed     Text format     Abstract available


  219. SELKER HP, Harris WS, Rackley CE, Marsh JB, et al
    Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial.
    Am Heart J. 2016;178:168-75.
    PubMed     Text format     Abstract available


  220. RIDKER PM, Amarenco P, Brunell R, Glynn RJ, et al
    Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Eve
    Am Heart J. 2016;178:135-44.
    PubMed     Text format     Abstract available


  221. KAUL P, Ohman EM, Knight JD, Anstrom KJ, et al
    Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary
    Am Heart J. 2016;178:55-64.
    PubMed     Text format     Abstract available


  222. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    PubMed     Text format     Abstract available


  223. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    PubMed     Text format     Abstract available


  224. AKERBLOM A, Clare RM, Lokhnygina Y, Wallentin L, et al
    Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
    Am Heart J. 2016;178:1-8.
    PubMed     Text format     Abstract available


    July 2016
  225. DOLL JA, Wang TY, Choudhry NK, Cannon CP, et al
    Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarct
    Am Heart J. 2016;177:33-41.
    PubMed     Text format     Abstract available


  226. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


  227. REN S, Hure A, Peel R, D'Este C, et al
    Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE).
    Am Heart J. 2016;177:58-65.
    PubMed     Text format     Abstract available


  228. DELGADO-LISTA J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, et al
    CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat
    Am Heart J. 2016;177:42-50.
    PubMed     Text format     Abstract available


  229. CHUN S, Choi Y, Chang Y, Cho J, et al
    Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women.
    Am Heart J. 2016;177:17-24.
    PubMed     Text format     Abstract available


  230. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    PubMed     Text format     Abstract available


  231. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    PubMed     Text format     Abstract available


    June 2016
  232. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    PubMed     Text format     Abstract available


  233. BLUMENTHAL JA, Feger BJ, Smith PJ, Watkins LL, et al
    Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
    Am Heart J. 2016;176:53-62.
    PubMed     Text format     Abstract available


  234. PATTI G, Cavallari I
    Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.
    Am Heart J. 2016;176:36-43.
    PubMed     Text format     Abstract available


  235. GONZALEZ HM, Tarraf W, Rodriguez CJ, Gallo LC, et al
    Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results.
    Am Heart J. 2016;176:134-44.
    PubMed     Text format     Abstract available


  236. JOUNI H, Askew JW, Crusan DJ, Miller TD, et al
    Temporal trends of single-photon emission computed tomography myocardial perfusion imaging in patients without prior coronary artery disease: A 22-year experience at a tertiary academic medical center.
    Am Heart J. 2016;176:127-33.
    PubMed     Text format     Abstract available


  237. VENTURA HO, Lavie CJ
    Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals.
    Am Heart J. 2016;176:125-6.
    PubMed     Text format    


  238. MCCARTHY CP, Mullins KV, Sidhu SS, Schulman SP, et al
    The on- and off-target effects of morphine in acute coronary syndrome: A narrative review.
    Am Heart J. 2016;176:114-21.
    PubMed     Text format     Abstract available


  239. PURI R, Nissen SE, Somaratne R, Cho L, et al
    Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Am Heart J. 2016;176:83-92.
    PubMed     Text format     Abstract available


  240. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    PubMed     Text format     Abstract available


  241. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    PubMed     Text format     Abstract available


  242. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    PubMed     Text format     Abstract available


  243. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    PubMed     Text format     Abstract available


    May 2016
  244. VAN DIJK PR, Mouden M, Hermanides R
    Directions for future trials on blood glucose-lowering drugs to improve left ventricular function post-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:e1.
    PubMed     Text format    


  245. XU H, Li W, Yang J, Wiviott SD, et al
    The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.
    Am Heart J. 2016;175:193-201.
    PubMed     Text format     Abstract available


  246. SILVERMAN MG, Morrow DA
    Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary?
    Am Heart J. 2016;175:172-4.
    PubMed     Text format    


  247. PILGRIM T, Vranckx P, Valgimigli M, Stefanini GG, et al
    Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:56-65.
    PubMed     Text format     Abstract available


  248. ERLINGE D, Koul S, Eriksson P, Schersten F, et al
    Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Am Heart J. 2016;175:36-46.
    PubMed     Text format     Abstract available


  249. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Ross-Fernandes MB, et al
    Corrigendum to 'The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)' [American Heart Journal 171/1 (2016) 73-81].
    Am Heart J. 2016;175:202-203.
    PubMed     Text format    


  250. VAN DIEPEN S, Lin M, Bakal JA, McAlister FA, et al
    Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?
    Am Heart J. 2016;175:184-92.
    PubMed     Text format     Abstract available


  251. PARSH J, Seth M, Briguori C, Grossman P, et al
    The optimal definition of contrast-induced acute kidney injury for prediction of inpatient mortality in patients undergoing percutaneous coronary interventions.
    Am Heart J. 2016;175:160-7.
    PubMed     Text format     Abstract available


  252. ARBEL Y, Qiu F, Bennell MC, Austin PC, et al
    Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study.
    Am Heart J. 2016;175:153-9.
    PubMed     Text format     Abstract available


  253. REED BN, Fox ER, Konig M, Jackevicius CA, et al
    The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action.
    Am Heart J. 2016;175:130-41.
    PubMed     Text format     Abstract available


  254. HUISMAN J, van der Heijden LC, Kok MM, Danse PW, et al
    Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
    Am Heart J. 2016;175:121-9.
    PubMed     Text format     Abstract available


  255. ALLEN NB, Lloyd-Jones D, Hwang SJ, Rasmussen-Torvik L, et al
    Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies.
    Am Heart J. 2016;175:112-20.
    PubMed     Text format     Abstract available


  256. DOBSON LE, Fairbairn TA, Musa TA, Uddin A, et al
    Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study.
    Am Heart J. 2016;175:101-11.
    PubMed     Text format     Abstract available


  257. SHAFIQ A, Arnold SV, Gosch K, Kureshi F, et al
    Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study.
    Am Heart J. 2016;175:94-100.
    PubMed     Text format     Abstract available


  258. SIDEBOTTOM AC, Sillah A, Miedema MD, Vock DM, et al
    Changes in cardiovascular risk factors after 5 years of implementation of a population-based program to reduce cardiovascular disease: The Heart of New Ulm Project.
    Am Heart J. 2016;175:66-76.
    PubMed     Text format     Abstract available


  259. SHIMADA YJ, Cannon CP, Liu Y, Wilson C, et al
    Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
    Am Heart J. 2016;175:18-27.
    PubMed     Text format     Abstract available


  260. MATHEWS R, Fonarow GC, Li S, Peterson ED, et al
    Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.
    Am Heart J. 2016;175:1-8.
    PubMed     Text format     Abstract available


    April 2016
  261. GARGIULO G, Costa F, Ariotti S, Biscaglia S, et al
    Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Am Heart J. 2016;174:95-102.
    PubMed     Text format     Abstract available


  262. GUIMARAES PO, Sun JL, Kragholm K, Shah SH, et al
    Association of standard clinical and laboratory variables with red blood cell distribution width.
    Am Heart J. 2016;174:22-8.
    PubMed     Text format     Abstract available


    March 2016
  263. BRIGUORI C, Visconti G, Donahue M, De Micco F, et al
    RenalGuard system in high-risk patients for contrast-induced acute kidney injury.
    Am Heart J. 2016;173:67-76.
    PubMed     Text format     Abstract available


  264. VASSALLI G, Klersy C, De Servi S, Galatius S, et al
    Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial.
    Am Heart J. 2016;173:1-7.
    PubMed     Text format     Abstract available


    February 2016
  265. PESARO AE, Granger CB, Lopes RD
    Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
    Am Heart J. 2016;172:42-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: